CLINICAL ROLE -
December 14 Pharmacy Week in Review: Walmart Announces New Telehealth Service for Veterans, Study Weighs Risks and Benefits of Statins
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Advances in Current and Emerging Therapies for Hemophilia
Tim Boonstra, RPh, Pharmacy Manager at Fairview Center for Bleeding and Clotting Disorders, talks about new therapies for hemophilia and exciting advancements on the horizon.
Depression and Burnout
In this video, David Hager, PharmD, BCPS, the director of clinical pharmacy services at UW Health, Madison, WI, discusses the relationship between burnout and depression.
Adherence With CDK 4/6 Inhibitors
Patient Management of CDK 4/6 Inhibitors
Dispensing of CDK4/6 Inhibitors
Multidisciplinary Approach: Managing CDK4/6 Inhibitors
Patients' Perspectives on CDK4/6 Inhibitors
Benefits and Challenges of CDK4/6 Inhibitors
Metastatic Breast Cancer: CDK4/6 Inhibitors
Improving Care for Patients With Metastatic Breast Cancer
Educating Patients and Staff on Using CDK4/6 Inhibitors
Best Practices for Managing Patients on CDK4/6 Inhibitors
Multidisciplinary Care in Breast Cancer
Considerations for Treating Patients with CDK4/6 Inhibitors
CDK4/6 Inhibitors in Metastatic Breast Cancer
Medically Integrated Pharmacy Teams Spur Innovations
Oral Oncolytics and Patient Adherence
Medically Integrated Dispensing Service Best Practices
Practical Challenges in Switching to CDK4/6 Inhibitors
The Efficacy and Safety of CDK4/6 Inhibitors
Roles of the Oncologist Versus Pharmacist
Multidisciplinary Approach to Managing Oral Oncolytics
The Advent of Oral Oncolytics and Patient Access
Vertical Integration and Looking Toward the Future
Impact of Competition on Pricing in the Future
Factors Determining Inclusion of Biosimilars on the Formulary
Educating the Patient and Providers on Biosimilars
Role of Specialty Pharmacy Regarding Biosimilars
Challenges for Payers With Costs of Biosimilars
